The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...
Lilly's strong entrenchment in insulin production should also help ... We sell different types of products and services to both investment professionals and individual investors.
The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.
Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...
Eli Lilly (LLY) stock rises as company posts Q4 2024 results, beating expectations with a twofold rise in revenue from weight ...
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results